Étude observationnelle ODYSSEE : durée de maintenance de la bithérapie metformine-sitagliptine versus metformine-sulfamides hypoglycémiants chez des patients diabétiques de type 2

The ODYSSÉE study compared the duration of maintenance of treatment in patients with type 2 diabetes (T2D) using dual therapy with either metformin and sitagliptin (M-Sita) or metformin and a sulfonylurea (M-SU) in adult patients with T2D who had responded inadequately to metformin monotherapy. Patient follow-up and changes to treatment were performed according to their GP's usual clinical practice. The primary outcome was time to change in treatment whatever the cause. The median treatment duration for patients in the M-Sita group (43.2 months) was significantly longer (P <0.0001) than in the M-SU group (20.2 months). This difference persisted after adjusting for baseline differences and confounders. Similar reduction in HbA1c were observed in both arms (-0.6%), though incidence of hypoglycemia was lower with M-Sita (9.7%) than with M-SU (21.0%) prior to treatment modification, and adverse events potentially related to treatment were similar in both groups (2,8% M-Sita vs. 2,7% M-SU). We conclude that under everyday conditions of primary care, maintenance of a dual therapy with M-Sita is longer than with M-SU, with similar HbA1c and a lower incidence of hypoglycemia.